Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

ABSTRACT:

SUBMITTER: Zibelman M 

PROVIDER: S-EPMC6685891 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature